{"entity":{"id":"paper-decision-sorafenib-lancet-2014","kind":"paper","name":"DECISION: sorafenib in radioactive iodine-refractory differentiated thyroid cancer","aka":[],"tldr":"Sorafenib was the first drug shown to delay progression in iodine-refractory differentiated thyroid cancer, adding about five months compared with placebo and opening the era of kinase inhibitors for the disease.","summary":"Phase 3 placebo-controlled trial of 417 patients with progressive radioactive iodine-refractory differentiated thyroid cancer randomised to sorafenib or placebo.\n\nMedian progression-free survival was 10.8 versus 5.8 months (hazard ratio 0.59) with response 12.2 versus 0.5 percent; hand-foot skin reaction, diarrhoea, alopecia and rash were common.","asOf":"2026-09-17","links":[{"label":"Lancet 2014","url":"https://doi.org/10.1016/S0140-6736(14)60421-9"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24768112/"}],"tags":[],"related":[],"cancers":["follicular-thyroid-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["decision-sorafenib"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2014,"doi":"10.1016/S0140-6736(14)60421-9","pmid":"24768112","authors":"Brose MS, Nutting CM, Jarzab B, et al.","paperType":"rct","findings":["Median progression-free survival 10.8 vs 5.8 months; hazard ratio 0.59.","Objective response 12.2 percent vs 0.5 percent."],"whatItMeans":"Sorafenib is an approved option for iodine-refractory thyroid cancer, now usually used after or instead of lenvatinib depending on tolerability.","caveats":["No overall survival benefit; response rate low compared with lenvatinib."],"changedPractice":true,"participants":417},"route":"/key-papers/paper-decision-sorafenib-lancet-2014/","neighbours":{"cancer":[{"id":"follicular-thyroid-cancer","kind":"cancer","name":"Follicular thyroid cancer","route":"/cancers/follicular-thyroid-cancer/"}],"drug":[{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/"}],"trial":[{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}